By Editorial TeamFDA clearance is a big deal, but it’s just the starting line for commercializing modern AI in healthcare. For vertical AI healthcare companies, especially the ones in the cardiac space, the thing that actually determines if they’ll survive and grow is a solid reimbursement pathway. If payers, both public and private, don’t have a clear way to pay for these advanced tools, even the most clinically brilliant AI is a complete non-starter.
Reimbursement: The Other Half of the Battle
Any healthcare venture partner or regulatory strategist worth their salt knows that a slick SaMD, even with a 510(k) or a De Novo clearance, is just a zombie company waiting to happen if it can’t show how it’s going to get paid. The Centers for Medicare and Medicaid Services (CMS) and the American Medical Association (AMA) are the ones who control the money. Their decisions, which are often painfully slow and complicated, are what decide if a new cardiac AI tool can get out of pilot programs and into actual clinical use. You have to evaluate a startup’s regulatory team with the same intensity you apply to its engineering team. A great QMS and a clear GMLP strategy are the floor, but if there isn’t an equally smart reimbursement strategy running alongside them, the whole investment is on shaky ground. The problem is particularly bad for disease-specific AI health platforms. Unlike general-purpose platforms that might get used for a dozen different things, vertical AI healthcare companies in cardiac prevention or oncology have to prove a very specific, data-backed value to get coverage. This means trying to navigate the messy and always-changing world of reimbursement, where not having a dedicated CPT code can put your commercial launch on ice indefinitely.
Working through the Labyrinth: HeartFlow’s CPT Code Journey
HeartFlow, which pioneered using AI to analyze CT scans for fractional flow reserve (FFR-CT) in coronary artery disease, is a perfect example of how to secure reimbursement. Their experience shows why you have to align your regulatory work with your reimbursement lobbying from day one. HeartFlow’s non-invasive technology was a huge step forward, but it needed a new payment mechanism to exist. The American Medical Association (AMA) has finally issued a Category I CPT code (75580) for FFR-CT, but it won’t even be effective until January 1, 2026, proof of how long these things take. This move away from older, temporary payment methods like New Technology Ambulatory Payment Classifications (NAPC) to a permanent Category I CPT code only happened because the company generated the real-world evidence (RWE) to justify it. CMS New Technology APC Payment Information The reimbursement rates CMS landed on, found in the Medicare Physician Fee Schedule, tell you exactly how the government values these services. For 2026, the professional fee for FFR-CT (75580) is set at $34, and for their Plaque Analysis (75577) it’s $41. For any venture partner, you have to know these numbers and the local coverage decisions from administrative contractors to have any hope of projecting a company’s real revenue potential. It’s a good sign that four of the seven Medicare Administrative Contractors (MACs) started covering HeartFlow Plaque Analysis back on November 24, 2024. By getting those early payment mechanisms sorted out, HeartFlow was able to build a substantial data moat and establish a lead in the CT-FFR space, creating a patent thicket that makes it difficult for new competitors to enter the market.
Cleerly’s Path: Category III CPT Codes and the Future of Cardiac AI
Cleerly, another major vertical AI healthcare company in the cardiac world, has used a different, but just as strategic, reimbursement playbook. Cleerly’s tech quantifies and characterizes coronary plaque from CT angiography (CTA) scans, going past a simple stenosis check to give a much fuller picture of atherosclerosis. This is a genuinely new diagnostic method, which pushes up against the limits of existing CPT codes. The American Medical Association (AMA) has issued Category I CPT codes for Cleerly’s tech as well, including CPT code 75577 for AI-QCT plaque analyses and CPT code 75580 for FFR estimates, with both also effective on January 1, 2026. This move from their previous Category III codes is a massive step toward getting permanent Category I CPT codes. Why does that matter? These codes are what allow the company to collect data on how often the tech is used, how effective it is, and how quickly doctors adopt it, all of which you need to make your case to payers. AMA CPT Category III Code Process For investors, seeing that a company has secured Category I codes, even if widespread reimbursement isn’t there yet, is a huge green light for future commercial success. It shows the company has actually managed to engage with the AMA and is on a clear path toward more stable and predictable revenue. This also draws a sharp line between Clinical Decision Support and Diagnostic AI. Cleerly’s product is Diagnostic AI, which is why it has to go through such rigorous regulatory and reimbursement screening.
The Vertical AI Advantage: Precision in Reimbursement
The experiences of HeartFlow and Cleerly show a core advantage that vertical AI healthcare companies have: their tight, disease-specific focus lets them build a more targeted and in the end successful reimbursement case.
- Clearer Value Proposition: By zeroing in on a specific need in cardiology, these companies can go to payers with a precise value proposition, showing exactly how their AI improves patient outcomes or cuts costs. This is a world away from horizontal platforms that can struggle to quantify their value across a dozen different applications.
- Targeted Evidence Generation: Vertical specialists can focus their clinical trials and RWE generation on the specific patient populations and endpoints that CMS and private payers actually care about for that one disease. This focused evidence is just far more persuasive.
- Strategic Regulatory-Reimbursement Alignment: The deep expertise inside a vertical company allows for much tighter integration between the regulatory strategy (like pursuing a Breakthrough Device Designation or a PCCP) and the reimbursement strategy (like engaging with the AMA for CPT codes or CMS for NAPC). Pulling off that kind of teamwork is often much harder for broad, general-purpose AI platforms. For venture partners and regulatory strategists, this means that even though the upfront investment to get reimbursement for a vertical AI solution is huge, the long-term payoff in market position and steady revenue streams is often worth it. Even the technical headaches of algorithmic drift and the need for continuous model validation become more manageable when you’re focused on a single disease area.
Evaluating a Startup’s Regulatory-Reimbursement Team
Given that getting paid is make-or-break, investors have to scrutinize a startup’s regulatory and reimbursement strategy with the same fire they bring to its technology. What should you be asking? * CPT Code Strategy: Does the company have an actual roadmap for getting Category I CPT codes? Are they actively talking with the AMA right now?
- Payer Engagement: What’s their plan for engaging with Aetna, Cigna, and the regional Medicare Administrative Contractors (MACs)? Have they gotten even one private payer to write a positive coverage policy?
- Evidence Generation: Is their clinical evidence strong enough to support a claim for payment? Are they actively generating RWE to make their case stronger?
- Regulatory Expertise: Does the team have people with deep experience in both FDA regulatory pathways (510(k), De Novo, Breakthrough Designation) and the brutal realities of CMS/AMA reimbursement processes?
- Financial Projections: Are their financial models grounded in reality, using realistic reimbursement rates and coverage timelines, or is it just a hockey-stick fantasy? The success of vertical AI healthcare companies like HeartFlow and Cleerly shows that regulatory clearance is just the first act. Your ability to get public and private payers to open their wallets is what really determines market survival and scale. This requires a strategic, integrated approach where you value your regulatory and reimbursement people as much as your brilliant engineers.
Methodology and Source Note
This analysis is based on publicly available information from the Centers for Medicare and Medicaid Services (CMS) and the American Medical Association (AMA), including the Medicare Physician Fee Schedule and CPT code announcements. Specific CPT code reimbursement rates for FFR-CT and Medicare administrative contractor coverage details were checked against official CMS publications. Our understanding of HeartFlow’s and Cleerly’s reimbursement paths comes from their public statements and industry reports. Medicare Physician Fee Schedule Lookup Tool
Frequently Asked Questions
Why is securing reimbursement pathways critical for cardiac AI companies, even after FDA clearance?
FDA clearance is only the initial step for cardiac AI companies. Without robust reimbursement pathways, even clinically effective AI solutions struggle to achieve market viability and sustainable growth. Payers, both public and private, need clear mechanisms to compensate for these advanced solutions, otherwise the AI becomes a non-starter for widespread clinical adoption.
What role do CMS and AMA play in the commercialization of cardiac AI, and why are they important to evaluate?
CMS and AMA are key gatekeepers to the financial viability of cardiac AI solutions. Their decisions dictate whether a novel solution can scale beyond pilot programs. Evaluating a startup’s reimbursement strategy and engagement with these bodies is as paramount as assessing its engineering prowess, as it directly impacts market penetration and revenue potential.
How does the transition from interim payment mechanisms or Category III CPT codes to Category I CPT codes impact commercial viability for cardiac AI solutions?
The transition to Category I CPT codes signifies broader adoption and the generation of real-world evidence necessary for advancements in cardiac AI. While Category III codes allow for data collection, Category I codes indicate recognition of the innovative nature and potential clinical utility by the AMA. This transition is a critical step towards establishing permanent, stable, and predictable reimbursement, signaling future commercial viability for investors.
What is the significance of the Medicare Physician Fee Schedule and Medicare Administrative Contractor (MAC) coverage determinations for cardiac AI companies?
The Medicare Physician Fee Schedule outlines CMS’s valuation of services, providing specific reimbursement rates for CPT codes like those for FFR-CT and Plaque Analysis. MAC coverage determinations indicate which regional contractors will cover these services. Understanding these rates and coverage decisions is vital for venture partners to accurately project a cardiac AI company’s revenue potential and market penetration.
